OTLK Stock Forecast & Price Target

Outlook Therapeutics is attractive because it has already secured marketing authorization for LYTENAVA in the European Union and United Kingdom, launched commercially in U.K., Germany, and Austria, and is showing improving European unit sales with a 46% increase versus Fiscal 2Q26. Its FDA appeal win in May 2026 and BLA resubmission on June 1, 2026 materially strengthen the U.S. launch case, where management expects first-year sales of $50 - 75 million and believes annual U.S. sales could exceed $500 million by 2030. Despite only about $0 million in Q3 revenue and $8 million in cash against $27 million in debt as of Q1, the combination of a differentiated ophthalmic anti-VEGF label, lean commercialization, and significant U.S. and European upside supports a positive fundamental outlook.

Outlook Therapeutics is a clinical-stage company whose outlook remains fragile because its commercialization story has only just begun and Q2 FY26 revenue was just $0.1 million versus estimates of $1.0 million and consensus of $4.4 million, while EPS of $(0.16) also missed expectations. The prior FDA Complete Response Letter on August 28, 2025, and the need to resubmit the BLA in November 2025 underscore persistent regulatory risk, and the stock’s roughly 50% drop from $1.32 on 7/23/26 suggests weak investor confidence despite the latest approval. With no Q2 guidance, ongoing balance-sheet and liquidity concerns, and execution risks around safety, efficacy, reimbursement, and commercialization, the fundamentals do not yet support a bullish view.